Image Source : ET Pharma
Glenmark Pharmaceuticals has achieved a major financial milestone following its landmark licensing agreement with USbased AbbVie, which is set to transform its capital structure and innovation trajectory.
Key Highlights:
-
Glenmark’s innovation arm, Ichnos Glenmark Innovation (IGI), signed a $1.925 billion deal for its oncology asset ISB 2001.
-
The agreement includes a $700 million upfront payment and up to $1.225 billion in milestonebased payouts.
-
S&P Global confirmed the deal will make Glenmark net cash positive, reversing its prior net debt position of ₹400 crore.
Strategic Impact:
-
The transaction eases Glenmark’s innovation funding burden, making IGI selfsustaining for the next 3–4 years.
-
Glenmark retains rights for emerging markets while AbbVie takes over development and commercialization in key global regions.
Market Reaction:
Shares surged over 30 percent postannouncement, with brokerages like Motilal Oswal and HSBC raising target prices.
Sources: CNBC TV18, Business Standard, Moneycontrol, MSN India, New Indian Express.
Advertisement
Advertisement